Can analysts adopt a bullish outlook for Cardiome Pharma Corp. (NASDAQ:CRME)?

April 16, 2018 - By Ellis Scott

Investors sentiment decreased to 0.46 in Q4 2017. Its down 0.63, from 1.09 in 2017Q3. It is negative, as 6 investors sold Cardiome Pharma Corp. shares while 7 reduced holdings. 2 funds opened positions while 4 raised stakes. 12.53 million shares or 7.45% less from 13.54 million shares in 2017Q3 were reported.
3.09M were accumulated by Putnam Invests Limited Liability Co. Jpmorgan Chase And Company invested 0% of its portfolio in Cardiome Pharma Corp. (NASDAQ:CRME). Gru One Trading Ltd Partnership has invested 0% in Cardiome Pharma Corp. (NASDAQ:CRME). Westfield Cap Limited Partnership reported 4.68M shares. Pennsylvania-based Alphaone Invest has invested 0% in Cardiome Pharma Corp. (NASDAQ:CRME). Art Limited Liability invested in 0% or 34,872 shares. Virtu Limited Liability Com accumulated 0% or 11,693 shares. Pnc Finance Ser Gp has 0% invested in Cardiome Pharma Corp. (NASDAQ:CRME). Natl Bank Of America Corp De accumulated 0% or 45 shares. Rock Springs Capital Limited Partnership accumulated 1.20 million shares. Comml Bank Of Montreal Can reported 0% in Cardiome Pharma Corp. (NASDAQ:CRME). The Massachusetts-based Clough Capital Prtnrs Limited Partnership has invested 0.34% in Cardiome Pharma Corp. (NASDAQ:CRME). Renaissance Technology Limited Liability Corporation reported 0% stake. Wells Fargo & Mn invested in 0% or 800 shares. The New York-based Morgan Stanley has invested 0% in Cardiome Pharma Corp. (NASDAQ:CRME).

Cardiome Pharma Corp. (NASDAQ:CRME) Ratings Coverage

Among 3 analysts covering Cardiome Pharma Corporation – Ordinary Shares (Canada) (NASDAQ:CRME), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cardiome Pharma Corporation – Ordinary Shares (Canada) had 5 analyst reports since November 15, 2017 according to SRatingsIntel. The firm has “Buy” rating by Mackie given on Wednesday, March 14. The stock of Cardiome Pharma Corp. (NASDAQ:CRME) earned “Buy” rating by Canaccord Genuity on Wednesday, November 15. The stock has “Buy” rating by H.C. Wainwright on Wednesday, April 4. The company was maintained on Wednesday, November 22 by H.C. Wainwright. The rating was upgraded by Mackie on Friday, December 15 to “Buy”. Below is a list of Cardiome Pharma Corp. (NASDAQ:CRME) latest ratings and price target changes.

04/04/2018 Broker: H.C. Wainwright Rating: Buy New Target: $9.5000 Maintain
14/03/2018 Broker: Mackie Rating: Buy New Target: $2.8 Maintain
15/12/2017 Broker: Mackie Rating: Buy Upgrade
22/11/2017 Broker: H.C. Wainwright Rating: Buy New Target: $9.5 Maintain
15/11/2017 Broker: Canaccord Genuity Rating: Buy Old Target: $8 New Target: $5 Maintain

The stock increased 1.27% or $0.03 during the last trading session, reaching $2.39. About 75,230 shares traded. Cardiome Pharma Corp. (NASDAQ:CRME) has declined 27.63% since April 16, 2017 and is downtrending. It has underperformed by 39.18% the S&P500.

Cardiome Pharma Corp., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of patients suffering from heart diseases. The company has market cap of $79.30 million. It offers BRINAVESS ) for the conversion of recent onset atrial fibrillation to sinus rhythm in adults; and AGGRASTAT, a reversible GP IIb/IIIa inhibitor for use in acute coronary syndrome patients. It currently has negative earnings. The firm also provides ESMOCARD and ESMOCARD LYO short-acting beta-blockers used to control rapid heart rate; XYDALBA, a semi-synthetic lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections; and TREVYENT for the treatment of pulmonary arterial hypertension.

Cardiome Pharma Corp. (NASDAQ:CRME) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.